logo
Can debt relief help with unpaid medical bills? What experts say

Can debt relief help with unpaid medical bills? What experts say

CBS News10-06-2025
We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms.
There are multiple debt relief (and DIY) options that can help you tackle your unpaid medical bills.
Getty Images
Despite recent efforts toward medical debt reform, many Americans still deal with piles of medical bills. A 2024 analysis from Peterson-KFF shows that about 20 million adults — nearly one in 12 — have unpaid medical debt. Around 14 million of those owe at least $1,000, while 3 million owe $10,000 or more.
"Most people don't worry about medical bills — until they do," says James Lambridis, CEO of debt relief platform DebtMD. "Medical bills usually come without warning, and they're often much more expensive than expected."
Compound these balances with other challenging factors like stubborn inflation, high interest rates, and economic policy concerns, and consumers are feeling the pressure to get out from under their medical debts.
For some, debt relief strategies may be able to help. Are you one of the millions of Americans looking to tackle medical debt? We asked some experts about your debt relief options.
Start tackling your medical debt here now.
Can debt relief help with unpaid medical bills?
If you're dealing with medical debt, there are several debt relief options you might explore. These include:
Credit counseling
The first option you might consider is credit counseling. Credit counselors can help you "Create a budget, prioritize payments, and can potentially assist with other high-interest debt to make the medical debt more affordable," says Thomas Nitzsche, a financial educator and vice president of public relations at Money Management International, a nonprofit credit counseling agency.
According to Nitzsche, about one in five of the company's customers come to them with medical debts.
"Credit counseling is highly recommended, especially when debt feels overwhelming," says Tayri Martinez-Orza, financial wellness expert and quality assurance expert at GreenPath Financial Wellness, a nonprofit financial counseling service. "It provides a fresh perspective and support by reviewing all of their debts — as well as their income and expenses — to help identify the most affordable and realistic repayment plan."
Best of all? It's typically free.
"A counselor gives you an in-depth debt analysis over the phone," says Howard Dvorkin, chairman of Debt.com. "There's no obligation, and you hang up knowing all your options and — most importantly — creating an accurate monthly budget."
Learn more about your credit counseling options here.
Debt settlement
Settlement may also be an option. This is when your debt relief company negotiates with your creditor (in this case, usually the hospital or doctor) to settle your debt for less than what you owe. You'll still need to make a payment, but it can often be significantly less than what you owe.
Settlement is more likely to be successful if you owe a large amount and can prove you have a financial hardship. In this case, it would benefit the creditor more to get some money from your account rather than none at all.
"Debt settlement is a viable option for individuals with unsecured debt exceeding $7,500, — including medical debt or medical debt placed on a credit card," says Natalia Brown, chief compliance officer at National Debt Relief.
Debt Management Plan (DMP)
Debt management plans could be an option, too, especially if medical debts aren't the only debts you're dealing with.
With a DMP, your debt relief provider handles repayment of all your debts on your behalf. You only make one flat payment to them each month, and they focus on putting those funds toward paying down your debts most efficiently.
Explore other strategies
Beyond debt relief, other strategies can help you tackle medical debt, too, experts say. First, you can negotiate.
"Your best option is to simply ask to pay less," Dvorkin says. "It sounds silly, but sometimes you shave dollars off your bill just by calling your healthcare provider and calmly explaining you can't afford to pay everything you owe right now. Sometimes, they'll ask what you can afford, so have a number in mind."
You can also ask about hardship options, financial assistance, or in-house payment plans, which could reduce your costs or help you spread them out over a longer period of time.
"Many hospitals offer financial assistance to help people burdened with medical care," Lambridis says. "Check to see if you meet their requirements to qualify. Even if you don't, your hospital may be able to put you on a more convenient payment plan."
Finally, always double-check your bills. Medical coding errors are common, and depending on your insurance coverage, they could cost you quite a bit.
"After receiving your bill, check to see if it's accurate," Lambridis says. "Look for overcharges, duplicate billing, or charges on services that you didn't receive. Medical bills can be difficult to understand. If you find yourself confused, contact your hospital's billing office."
You can also speak to a medical billing advocate. They can help you decipher medical bills and ensure your charges match the services you actually received — and that your insurance was correctly applied to those charges.
Don't use credit cards or loans (and don't wait)
Whatever you do, try to avoid using credit cards or loans to pay off medical debt. Thanks to recent credit reporting changes, failing to repay medical bills should not have an adverse effect on your credit — but not paying credit cards or loans will.
Additionally, medical providers are typically slower to send debts to collections, as it takes a while for billing and insurance payments to be sorted out. This could give you more time to pay off your bills, especially with a payment plan.
Finally, credit cards and loans can come with high rates. The current average rate on a credit card is over 21%.
"Placing medical debt on credit cards can be less effective, especially in a high-interest environment," Brown says. "Doing this often leads to even more expensive balances since interest can accrue on credit cards if the full balance isn't paid monthly."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Warner Bros. earnings, Fed talk, jobless claims: What to Watch
Warner Bros. earnings, Fed talk, jobless claims: What to Watch

Yahoo

time22 minutes ago

  • Yahoo

Warner Bros. earnings, Fed talk, jobless claims: What to Watch

Asking for a Trend host Josh Lipton takes a look at the top stories for investors to watch on Thursday, Aug. 7. In the morning, Eli Lilly (LLY), Toyota (TM), ConocoPhillips (COP), Constellation Energy (CEG), and Warner Bros. Discovery (WBD) will report earnings. In the afternoon, Take-Two (TTWO) will report results. Atlanta Federal Reserve President Raphael Bostic will deliver remarks. Initial jobless claims data for the week ending Aug. 2 will be posted in the morning. Economists are expecting an uptick from the previous reporting period. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend. Time now for what to watch Thursday, August 7th, starting off on the earnings front. No rest for the weary this earnings season. We'll be getting some more reports on Thursday. It's going to include Eli Lilly, Toyota and Take Two Interactive. Eli Lilly announced the results for the second quarter before the markets open. Obesity drugs will remain in focus for Eli Lilly and new drugs in the pipeline. It's coming against the backdrop of President Trump's looming tariffs on the pharma industry, and also saying the company's full year financial guidance could also be raised barring any major surprises in the quarter. And turning to the Federal Reserve, Atlanta Fed President Rafael Bostic is speaking on Thursday. This is coming after continuing commentary from President Trump around a potential successor for Fed Chair Jerome Powell. Trump saying on Tuesday that the list is down to four people, but that Treasury Secretary Scott Bessette will not be nominated for that role. And finally, we're going to be getting some fresh jobs data on Thursday with weekly initial jobless claims, economists forecasting claims to tick up to 222,000, signaling what could be more softening in the labor market.

Paramount's co-CEO Robbins to step down, memo shows
Paramount's co-CEO Robbins to step down, memo shows

Yahoo

time22 minutes ago

  • Yahoo

Paramount's co-CEO Robbins to step down, memo shows

By Juby Babu (Reuters) -Brian Robbins, who helped grow the Paramount+ streaming service, is stepping down as Paramount Global's co-CEO, according to a memo seen by Reuters on Wednesday, following the completion of its merger with Skydance Media. David Ellison, the CEO of Skydance, will lead the new company as chief executive after the merger is completed by August 7. "The company is in exceptionally capable hands with David Ellison and the incoming team from Skydance," Robbins said in the memo. Robbins, who joined the company in 2017, was appointed co-CEO in April last year, along with George Cheeks and Chris McCarthy, with the three collectively succeeding Bob Bakish. McCarthy's departure was reported last month, while Cheeks will remain with the company as its chair of media, overseeing its broadcast and cable television business. Robbins was named CEO of Nickelodeon in 2018, and became the chief of Paramount Pictures in 2021. As CEO of Paramount Pictures, Robbins has overseen 17 number one releases at the box office and has overseen franchises including "Sonic the Hedgehog," "A Quiet Place," and "Mission: Impossible." After the deal closes, the company is expected to be structured into three primary business segments - studios, direct-to-consumer and TV media.

MetLife (NYSE:MET) Misses Q2 Revenue Estimates, Stock Drops
MetLife (NYSE:MET) Misses Q2 Revenue Estimates, Stock Drops

Yahoo

time22 minutes ago

  • Yahoo

MetLife (NYSE:MET) Misses Q2 Revenue Estimates, Stock Drops

Global insurance giant MetLife (NYSE:MET) fell short of the market's revenue expectations in Q2 CY2025, with sales falling 7.2% year on year to $17.34 billion. Its non-GAAP profit of $2.02 per share was 6.3% below analysts' consensus estimates. Is now the time to buy MetLife? Find out in our full research report. MetLife (MET) Q2 CY2025 Highlights: Net Premiums Earned: $12.75 billion vs analyst estimates of $11.15 billion (1.2% year-on-year decline, 14.4% beat) Revenue: $17.34 billion vs analyst estimates of $18.64 billion (7.2% year-on-year decline, 7% miss) Pre-Tax Profit Margin: 5.7% (flat year on year) Adjusted EPS: $2.02 vs analyst expectations of $2.16 (6.3% miss) Market Capitalization: $50.99 billion Company Overview Founded in 1863 by a group of New York businessmen during the Civil War era, MetLife (NYSE:MET) is a global financial services company that provides insurance, annuities, employee benefits, and asset management services to individuals and businesses worldwide. Revenue Growth Insurance companies generate revenue three ways. The first is the core insurance business itself, represented in the income statement as premiums earned. The second source is investment income from investing the 'float' (premiums collected but not yet paid out as claims) in assets such as fixed-income assets and equities. The third is fees from policy administration, annuities, and other value-added services. Unfortunately, MetLife's 2.7% annualized revenue growth over the last five years was sluggish. This was below our standards and is a rough starting point for our analysis. Long-term growth is the most important, but within financials, a half-decade historical view may miss recent interest rate changes and market returns. MetLife's recent performance shows its demand has slowed as its revenue was flat over the last two years. Note: Quarters not shown were determined to be outliers, impacted by outsized investment gains/losses that are not indicative of the recurring fundamentals of the business. This quarter, MetLife missed Wall Street's estimates and reported a rather uninspiring 7.2% year-on-year revenue decline, generating $17.34 billion of revenue. Net premiums earned made up 69.8% of the company's total revenue during the last five years, meaning insurance operations are MetLife's largest source of revenue. Net premiums earned commands greater market attention due to its reliability and consistency, whereas investment and fee income are often seen as more volatile revenue streams that fluctuate with market conditions. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Book Value Per Share (BVPS) Insurance companies are balance sheet businesses, collecting premiums upfront and paying out claims over time. The float–premiums collected but not yet paid out–are invested, creating an asset base supported by a liability structure. Book value per share (BVPS) captures this dynamic by measuring these assets (investment portfolio, cash, reinsurance recoverables) less liabilities (claim reserves, debt, future policy benefits). BVPS is essentially the residual value for shareholders. We therefore consider BVPS very important to track for insurers and a metric that sheds light on business quality. While other (and more commonly known) per-share metrics like EPS can sometimes be lumpy due to reserve releases or one-time items and can be managed or skewed while still following accounting rules, BVPS reflects long-term capital growth and is harder to manipulate. MetLife's BVPS declined at a 15.6% annual clip over the last five years. On a two-year basis, BVPS fell at a slower pace, dropping by 5.4% annually from $39.96 to $35.79 per share. Over the next 12 months, Consensus estimates call for MetLife's BVPS to grow by 71% to $56.10, elite growth rate. Key Takeaways from MetLife's Q2 Results We were impressed by how significantly MetLife blew past analysts' net premiums earned expectations this quarter. On the other hand, its revenue missed and its book value per share fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 5.9% to $71.56 immediately following the results. MetLife's latest earnings report disappointed. One quarter doesn't define a company's quality, so let's explore whether the stock is a buy at the current price. We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store